Investor Lists

Biotech investors in China

Updated 7 November 2026

Firms observed backing a biotech company in China in the last two years, wherever the firm is based.

See all 46 →The top 25
46investors on the listNo change this week
532cheques in 12 months+12% against the market
$30Mmedian round they joined+281% against the market median
100%wrote a cheque in 12 months
43%have led a round

The Top 25

Ordered by cheques observed, never by anything anyone paid for

Deploying now (25)

  1. 1Qiming Venture PartnersDeploying nowVC firm · Hong Kong SAR China526$25Mmedian roundOct 2026last seen
  2. 2IDG CapitalDeploying nowPrivate equity · China504$25Mmedian roundOct 2026last seen
  3. 3HSGDeploying nowVC firm · Hong Kong SAR China498$31Mmedian roundOct 2026last seen
  4. 4Shenzhen Capital Group Co.Deploying nowGovernment · China449$16Mmedian roundOct 2026last seen
  5. 5OrbiMedDeploying nowPrivate equity · United States447$71Mmedian roundOct 2026last seen
  6. 6Shunwei CapitalDeploying nowVC firm · China288$15Mmedian roundOct 2026last seen
  7. 7Hill House CapitalDeploying nowFamily office · Singapore248$60Mmedian roundSept 2026last seen
  8. 8Gobi PartnersDeploying nowVC firm · Malaysia212$10Mmedian roundOct 2026last seen
  9. 9Gaorong CapitalDeploying nowVC firm · China184$30Mmedian roundNov 2026last seen
  10. 10Vivo CapitalDeploying nowPrivate equity · United States140$64Mmedian roundSept 2026last seen
  11. 11Eli LillyDeploying nowCorporate VC · United States137$56Mmedian roundNov 2026last seen
  12. 125Y CapitalDeploying nowVC firm · China126$28Mmedian roundOct 2026last seen
  13. 13Oriza HoldingsDeploying nowVC firm · China101$14Mmedian roundOct 2026last seen
  14. 14TCG CrossoverDeploying nowVC firm · United States60$150Mmedian roundOct 2026last seen
  15. 15Boyu CapitalDeploying nowPrivate equity · Hong Kong SAR China20$260Mmedian roundOct 2026last seen
  16. 16Decheng CapitalDeploying nowVC firm · United States17$35Mmedian roundSept 2026last seen
  17. 17GL VenturesDeploying nowVC firm6$39Mmedian roundNov 2026last seen
  18. 18Yunmu CapitalDeploying nowVC firm · China3$30Mmedian roundOct 2026last seen
  19. 19Guofang Venture CapitalDeploying nowVC firm3$200Mmedian roundNov 2026last seen
  20. 20Cenova CapitalDeploying nowGrowth equity · China2$75Mmedian roundMay 2026last seen
  21. 21China Life CapitalDeploying nowVC firm2$1.3Bmedian roundOct 2026last seen
  22. 22Seas CapitalDeploying nowVC firm · China2$21Mmedian roundMar 2026last seen
  23. 23LAVDeploying nowGrowth equity2$100Mmedian roundMay 2026last seen
  24. 24Dalton VentureDeploying nowVC firm · China1$22Mmedian roundMar 2026last seen
  25. 25LiepinDeploying nowCorporate VC1$22Mmedian roundMar 2026last seen
21 more on this list

All 46 are in the app, with filters for stage, sector and market. A free account shows 10 per search, Pro up to 1,000.

See the whole list →

Reading for founders in health and biotech

More books for founders and investors on the Reading List.

As an Amazon Associate we earn from qualifying purchases.

Quick answers about biotech investors in China

Who are the most active biotech investors in China?

By cheques observed, the most active are Qiming Venture Partners, IDG Capital, HSG, Shenzhen Capital Group Co. and OrbiMed.

How many biotech investors in China are there?

46 are on record. 100% made an investment in the last 12 months and 43% have led a round.

Which stages do biotech investors in China back?

Of the rounds with a named stage in the last 12 months, mostly Series B (24%) and Series A (21%).

How big are the rounds biotech investors in China join?

The typical (median) round among the leading investors here is $31M.

Which sectors do biotech investors in China back most?

In the last 12 months, mostly Biotech, AI and Healthcare.

Which biotech investors in China lead the most rounds?

OrbiMed (9 led), Qiming Venture Partners (8 led) and IDG Capital (8 led).

Where are biotech investors in China based?

Among the most active, most are based in China (10), the United States (5) and Hong Kong SAR China (3).

What have biotech investors in China invested in recently?

Recent rounds include T-Therapeutics (Series B, Nov 2026, with Eli Lilly), Sand.ai (Series A, Nov 2026, with Guofang Venture Capital) and Nanochap (Series C, Nov 2026, with Gaorong Capital).

Built from the rounds we watched, refreshed every night. How we count · Report a correction